2,3,7,8-Tetrabromodibenzo-4-dioxin

• Identification
• Experimental evidence
• Physicochemical properties
• ADMET properties
• Chemical-gene interaction
• Descriptors
• Presence in chemical regulation or guideline
• Presence in human biospecimen

Literature identifier	Study type	Test dosage	Effective dosage	Endocrine-mediated endpoints	Systems-level perturbations
DOI:10.1016/0045-6535(92)90467-6	IVR	0.000001 - 0.0005 mmol/kg	0.000001 - 0.0001 mmol/kg	Affects xenobiotic metabolism	Metabolic endocrine-mediated perturbations
PMID:17447562	IVTH	0.000000004 - 0.000004 M	0.000000004 - 0.000004 M	Affects corticosterone metabolism	Metabolic endocrine-mediated perturbations;Neurological endocrine-mediated perturbations
	IVTH	0.000000004 - 0.000004 M	0.000000004 - 0.000004 M	Affects steroidogenesis	Reproductive endocrine-mediated perturbations
PMID:8248944	IVR	0.0001 mg/kg	0.0001 mg/kg	Increase in T3 levels	Metabolic endocrine-mediated perturbations
	IVR	0.0001 mg/kg	0.0001 mg/kg	Decrease in T4 levels	Metabolic endocrine-mediated perturbations
	IVR	0.01 mg/kg	0.01 mg/kg	Increased Aspartate aminotransferase (AST) levels	Hepatic endocrine-mediated perturbations
	IVR	0.01 mg/kg	0.01 mg/kg	Decreased thymus gland weights	Immunological endocrine-mediated perturbations
	IVR	0.01 mg/kg	0.01 mg/kg	Decreased triglycerides level	Metabolic endocrine-mediated perturbations
	IVR	0.01 mg/kg	0.01 mg/kg	Increased Alanine aminotransferase (ALT) levels	Hepatic endocrine-mediated perturbations
	IVR	0.01 mg/kg	0.01 mg/kg	Changes in haemocrit values	Immunological endocrine-mediated perturbations
	IVR	0.00001 mg/kg	-	No significant effects observed	-
	IVR	0.001 mg/kg	0.001 mg/kg	Decreased triglycerides level	Metabolic endocrine-mediated perturbations
	IVR	0.001 mg/kg	0.001 mg/kg	Increased Aspartate aminotransferase (AST) levels	Hepatic endocrine-mediated perturbations
	IVR	0.001 mg/kg	0.001 mg/kg	Changes in haemocrit values	Immunological endocrine-mediated perturbations
	IVR	0.001 mg/kg	0.001 mg/kg	Decreased thymus gland weights	Immunological endocrine-mediated perturbations
	IVR	0.001 mg/kg	0.001 mg/kg	Increased Alanine aminotransferase (ALT) levels	Hepatic endocrine-mediated perturbations
	IVR	0.003 mg/kg	0.003 mg/kg	Decreased triglycerides level	Metabolic endocrine-mediated perturbations
	IVR	0.003 mg/kg	0.003 mg/kg	Increased Aspartate aminotransferase (AST) levels	Hepatic endocrine-mediated perturbations
	IVR	0.003 mg/kg	0.003 mg/kg	Decreased thymus gland weights	Immunological endocrine-mediated perturbations
	IVR	0.003 mg/kg	0.003 mg/kg	Changes in haemocrit values	Immunological endocrine-mediated perturbations
	IVR	0.003 mg/kg	0.003 mg/kg	Increased Alanine aminotransferase (ALT) levels	Hepatic endocrine-mediated perturbations

---

DISCLAIMER

We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.